Systemic failures in trans healthcare are causing forced infertility. When people are denied timely access to sperm or egg freezing before starting hormones or surgery, or pushed through pathways too slowly to preserve that option, the loss is permanent. This is not an abstract risk: it is a predictable, preventable harm that healthcare systems are causing right now.
What fertility preservation actually means for trans people
Fertility preservation is the process of storing reproductive material, sperm, eggs, or embryos, before medical treatment that may affect the ability to have biological children later. For trans people, that treatment is most commonly hormone therapy or gender-affirming surgery. Neither hormones nor surgery automatically end fertility, but both can do so, and in some cases the change is irreversible.
Testosterone can suppress ovulation and affect egg quality, sometimes temporarily and sometimes not. Oestrogen and anti-androgens suppress sperm production, again with variable recovery. Surgeries that remove the testes, ovaries, or uterus end fertility completely. None of these outcomes has to be a surprise. They are known, they are foreseeable, and there are well-established ways to preserve options before the point of no return, if the system acts in time.
Sperm freezing is straightforward, relatively inexpensive, and can be done quickly. Egg freezing is more involved, requiring hormonal stimulation over several weeks and a surgical retrieval, but it is a routine procedure in reproductive medicine. Embryo freezing follows a similar process. The science exists. The question is whether trans people are being given access to it before it is too late.
How the system is failing: the specific mechanisms of harm
The failures here are not random or inevitable. They follow a pattern, and naming that pattern matters because each point in it is a place where the harm could have been prevented.
Fertility counselling is not happening consistently
Many trans people go through the early stages of a gender pathway, including initial assessments and the start of hormones, without a single meaningful conversation about fertility. The question of whether they might want biological children, and what preserving that possibility would require, simply does not come up. Sometimes a leaflet is handed over. More often, nothing is said at all.
This is a serious clinical failure. In any other area of medicine where treatment carries a risk of infertility, such as chemotherapy or certain surgical procedures, the standard of care includes explicit discussion of preservation options before treatment begins. Trans healthcare should be no different, and the fact that it routinely falls short of this standard is not a minor administrative gap. It changes people's lives permanently.
Waiting lists are destroying the window of opportunity
In many countries, and in the UK in particular, the wait to access gender-affirming care through public services runs into years. By the time a person reaches the point of starting hormones, they may have spent two, three, or four years in a queue. During that time, nobody has told them to think about fertility preservation, because the clinical relationship has not yet properly begun.
When they finally reach the front of the queue, they are often in their mid-twenties or older, having started waiting as teenagers. The urgency to begin treatment is entirely understandable; they have waited long enough. But the fertility conversation, if it happens at all, happens at the last moment, with no time built in for the person to think clearly, access funding, or go through the preservation process at a pace that suits them.
For trans boys and young men assigned female at birth, egg freezing requires weeks of hormonal preparation. If that conversation happens on the day someone is finally handed a prescription for testosterone, the window has effectively been closed by the system's own delay.
Cost is a barrier that the system ignores
Sperm freezing is relatively affordable, but egg and embryo freezing are not. A single cycle of egg freezing, including the drugs, the retrieval, and the storage, typically costs thousands of pounds or dollars, and that is before any attempt at using the material. Public funding for fertility preservation in the context of trans healthcare is inconsistent at best and absent at worst.
People who cannot afford it lose the option. That means the harm falls hardest on those with the least financial resource, which is a familiar pattern in healthcare inequality, but no less troubling for being familiar. A system that allows permanent, life-altering harm to concentrate among the poorest people in a group that already faces significant disadvantage has something serious to answer for.
Fertility clinics are not always trans-inclusive
Even when a trans person knows they want to preserve fertility, knows the process, and can find the money, they may then encounter a fertility clinic that is not equipped or willing to work with them. That can mean a clinic that does not know how to adjust its protocols for a trans patient's anatomy or hormonal profile, a clinic whose forms and language make a trans man feel invisible or unwelcome, or, in the worst cases, a clinic that refuses to treat them at all.
This is not a theoretical problem. Trans people tell me about it. The reproductive medicine world has not caught up with the reality that trans people exist, that they have reproductive bodies, and that they deserve the same standard of care as anyone else. Until it does, the gap between what is technically possible and what is practically accessible will keep causing harm.
Who is most affected
The consequences of these failures are not evenly distributed. Trans young people are particularly vulnerable, because they may not have had the opportunity to think through questions about parenthood before they reach the point of needing to decide. A seventeen-year-old starting testosterone deserves to have the fertility conversation, clearly and kindly, with enough time to actually act on it. Too often, that conversation does not happen, or happens so late that it is a formality rather than a genuine choice.
Trans women and trans feminine people who want to freeze sperm face a specific timing challenge. Oestrogen and anti-androgens begin affecting sperm production relatively quickly, and sperm quality and quantity can decline within months of starting feminising hormones. The window for freezing is not unlimited, and if no one raises it at the start of the pathway, it may quietly close before the person even realises it was open.
Trans men and trans masculine people face the additional complexity that egg freezing requires a temporary interruption or delay in testosterone, which can be distressing for someone whose wellbeing is already tied up in starting or continuing that treatment. The emotional cost of that interruption deserves to be acknowledged and supported, not minimised. A system that treats the fertility question as an administrative checkbox rather than a human conversation is going to fail people at precisely the moment they most need good care.
The framing matters: this is not an inevitable side effect
I want to push back against a way of thinking about this that I come across quite often, which is the idea that infertility is simply a trade-off that comes with transition, and that people who transition know what they are signing up for. That framing is wrong, and it is harmful.
When a trans person loses fertility because no one told them preservation was possible, or because the waiting list ran past the window of opportunity, or because they could not afford a procedure that was never publicly funded, they have not made a choice. They have had a choice removed from them by a system that failed at its basic obligations. That is a forced outcome, not an informed trade-off, and the difference between those two things is profound.
Transition does not require infertility. For many trans people it may lead there, but that is a consequence of specific medical interventions, and those interventions can in many cases be sequenced around a fertility preservation step, if the system is designed to support that. The question is whether the system is designed to support it. Right now, in most places, it is not.
What good care looks like
Good care means raising fertility as a conversation at the very beginning of a trans person's engagement with healthcare services, not at the point when hormones are about to start. It means giving people time, real time, not a five-minute conversation at the end of an appointment, to think about whether biological parenthood matters to them and what they want to do about it.
It means public funding for fertility preservation in the context of gender-affirming care, because the alternative is a system that allows permanent harm to fall on those who can least afford to avoid it. It means fertility clinics that are trained to work with trans patients and whose environments are affirming rather than alienating. And it means treating the question of reproductive futures with the same seriousness that medicine brings to any other situation where treatment may affect fertility.
None of this is radical. It is just competent, humane healthcare, applied consistently to a group of people who have been consistently under-served. The gap between what is possible and what is currently happening is not a medical mystery. It is a political and organisational failure, and it has permanent consequences for real people.
If there is a topic that you would like me to cover, just let Sammy know.
Dr Helen Webberley is a Gender Specialist, Medical Educator, writer, and advocate, and the founder of GenderGP. She writes about gender diversity, trans healthcare, and the lives around them.
Comments